Product Description & Research Overview
Melanotan II is a synthetic melanocortin peptide originally developed to investigate alternatives to ultraviolet (UV) tanning. It works by activating melanocortin receptors throughout the body, stimulating melanin production while also influencing pathways involved in sexual function, appetite regulation, and mood.
Unlike topical tanning products, Melanotan II promotes the body’s own production of melanin, allowing researchers to study natural pigmentation responses with reduced reliance on UV exposure. Beyond pigmentation, activation of melanocortin receptors has generated significant research interest for its effects on libido, erectile function, appetite suppression, metabolic regulation, and photoprotection.
Researchers continue to investigate Melanotan II as a multi-functional peptide because it acts on several melanocortin receptor subtypes simultaneously, producing both pigment-related and systemic physiological effects. It has become one of the most extensively studied melanocortin peptides for skin pigmentation, sexual health, appetite regulation, and UV protection, although much of the available evidence remains preclinical or observational.
Research suggests Melanotan II produces its effects through several complementary mechanisms:
Timing: Morning administration is commonly researched. When investigating sexual function, administration approximately 2–4 hours before activity is often studied. Splitting larger daily doses may help improve tolerability.
Reconstitution (10 mg Vial)
Step 1
Add 2.0 mL diluent.
Creates a 5.0 mg/mL solution.
Step 2
Draw 20 units for a 1 mg dose.
Quick Reference
Frequency: Commonly 2–3 times per week after loading
Doses per vial: 10 doses (at 1 mg)
Approximate vial duration: Approximately 3 weeks (depending on protocol)
Disclaimer
For research use only. Not for human consumption.
The dosing information provided is intended solely for laboratory and research purposes and is not medical advice. Always consult qualified professionals regarding research protocols.
These statements have not been evaluated by Health Canada or the U.S. Food and Drug Administration (FDA).
Research suggests Melanotan II produces its effects through several complementary mechanisms:
Timing: Morning administration is commonly researched. When investigating sexual function, administration approximately 2–4 hours before activity is often studied. Splitting larger daily doses may help improve tolerability.
Reconstitution (10 mg Vial)
Step 1
Add 2.0 mL diluent.
Creates a 5.0 mg/mL solution.
Step 2
Draw 20 units for a 1 mg dose.
Quick Reference
Frequency: Commonly 2–3 times per week after loading
Doses per vial: 10 doses (at 1 mg)
Approximate vial duration: Approximately 3 weeks (depending on protocol)
Initial Response
Early Systemic Effects
Pigmentation Changes
Continued Benefits
Initial Response
Early Systemic Effects
Pigmentation Changes
Continued Benefits
Research suggests Melanotan II produces its effects through several complementary mechanisms:
Timing: Morning administration is commonly researched. When investigating sexual function, administration approximately 2–4 hours before activity is often studied. Splitting larger daily doses may help improve tolerability.
Reconstitution (10 mg Vial)
Step 1
Add 2.0 mL diluent.
Creates a 5.0 mg/mL solution.
Step 2
Draw 20 units for a 1 mg dose.
Quick Reference
Frequency: Commonly 2–3 times per week after loading
Doses per vial: 10 doses (at 1 mg)
Approximate vial duration: Approximately 3 weeks (depending on protocol)
Initial Response
Early Systemic Effects
Pigmentation Changes
Continued Benefits
